genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2016
Alexza Pharmaceuticals
Industry News
Ferrer to Acquire Alexza Pharmaceuticals
A-Lists
41 Companies at Risk for Delisting
A-Lists
26 Companies at Risk for Delisting
A-Lists
Top 17 Serial Bio Entrepreneurs
News
Alexza Receives $10M from Grupo Ferrer in Deal for MAA-Ready Inhaled Antipsychotic
News
Biovail Returns U.S. and Canadian Rights for Staccato Loxapine to Alexza
News
Cypress Pays Alexza $5M to Use Technology with Smoking Cessation Therapy
Drug Discovery
Alexza to Obtain $16.4M in Registered Direct Offering
News
Biovail Ponies Up $40M for North American Rights to Inhaled Version of Therapy for Schizophrenia Symptoms
News
Alexza Enters into $50M Development Collaboration for Two Products
Scroll Up
Scroll Up
